Kind Pharmaceuticals Announces Settlement
Kind Pharmaceuticals Announces Settlement
HANGZHOU, China, April 16, 2024 /PRNewswire/ -- Today, Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC ("Kind Pharmaceuticals"), together with its Chief Executive Officer Dr. Dong Liu and Chief Scientific Officer Dr. Shaojiang Deng, announced a resolution of their recent dispute with FibroGen, Inc. regarding Kind Pharmaceuticals' hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF- PHI) technology. The parties have agreed to withdraw all pending legal proceedings between them regarding this HIF-PHI technology, without payment by either party.
HIF-PHIs are a class of compounds that can be used to treat anemia. Kind Pharmaceuticals' HIF-PHI drug candidate, AND017, is currently being studied in a clinical trial for the treatment of anemia in chronic kidney disease (CKD) patients. As a result of the settlement, Kind Pharmaceuticals remains free to develop AND017 and other HIF-PHIs in its pipeline. Dr. Liu, Chief Executive Officer of Kind, commented: "Kind is pleased that these disputes have been fully and finally resolved. With these disputes behind us, Kind can now focus on advancing its innovative pipeline of products to the market."
Contact: Dong Liu, [email protected]
SOURCE Kind Pharmaceuticals
HANGZHOU, China, April 16, 2024 /PRNewswire/ -- Today, Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC ("Kind Pharmaceuticals"), together with its Chief Executive Officer Dr. Dong Liu and Chief Scientific Officer Dr. Shaojiang Deng, announced a resolution of their recent dispute with FibroGen, Inc. regarding Kind Pharmaceuticals' hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF- PHI) technology. The parties have agreed to withdraw all pending legal proceedings between them regarding this HIF-PHI technology, without payment by either party.
中國杭州，2024年4月16日 /PRNewswire/ — 今天，杭州安道製藥有限公司和Kind Pharmicals LLC（“Kind Pharmicals”）及其首席執行官劉東博士和首席科學官鄧少江博士宣佈解決他們最近與FibroGen, Inc.就Kind Pharmaceuticals的缺氧誘導因子脯氨酸酶抑制劑（HIF-PHI）技術發生的爭議。雙方同意撤回他們之間關於這種HIF-PHI技術的所有未決法律訴訟，無需任何一方付款。
HIF-PHIs are a class of compounds that can be used to treat anemia. Kind Pharmaceuticals' HIF-PHI drug candidate, AND017, is currently being studied in a clinical trial for the treatment of anemia in chronic kidney disease (CKD) patients. As a result of the settlement, Kind Pharmaceuticals remains free to develop AND017 and other HIF-PHIs in its pipeline. Dr. Liu, Chief Executive Officer of Kind, commented: "Kind is pleased that these disputes have been fully and finally resolved. With these disputes behind us, Kind can now focus on advancing its innovative pipeline of products to the market."
HIF-PHIS 是一類可用於治療貧血的化合物。Kind Pharmaceuticals的HIF-PHI候選藥物 AND017 目前正在一項臨床試驗中進行研究，用於治療慢性腎臟病（CKD）患者的貧血。和解協議的結果是，Kind Pharmicals仍然可以自由開發 AND017 和正在研發的其他 HIF-PHIS。Kind首席執行官劉博士評論說：“Kind很高興這些爭議最終得到全面解決。這些爭議已經過去，Kind現在可以專注於將其創新產品推向市場。”
Contact: Dong Liu, [email protected]
聯繫人：劉東，[email protected]
SOURCE Kind Pharmaceuticals
來源 Kind 製藥公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧